Association of High-Potency Cannabis Use With Mental Health and Substance Use in Adolescence

Overview

Journal JAMA Psychiatry

Publisher American Medical Association

Specialty Psychiatry

Date 2020 May 28

PMID 32459328

Citations 54

Authors

Lindsey A Hines

Tom P Freeman

Suzanne H Gage

Stanley Zammit

Matthew Hickman

Mary Cannon

Marcus Munafo

John Macleod

Jon Heron

Affiliations

Soon will be listed here.

Abstract

Importance: Cannabis use is consistently linked to poorer mental health outcomes, and there is evidence that use of higher-potency cannabis increases these risks. To date, no studies have described the association between cannabis potency and concurrent mental health in a general population sample or addressed confounding using longitudinal data.

Objective: To explore the association between cannabis potency and substance use and mental health outcomes, accounting for preceding mental health and frequency of cannabis use.

Design, Setting, And Participants: This cohort study used data from the Avon Longitudinal Study of Parents and Children, a UK birth cohort of participants born between April 1, 1991, and December 31, 1992. Present data on outcomes and exposures were collected between June 2015 and October 2017 from 1087 participants at 24 years of age who reported recent cannabis use.

Exposures: Self-reported type of cannabis most commonly used in the past year, coded to a binary exposure of use of high-potency cannabis or lower-potency cannabis.

Main Outcomes And Measures: Outcomes were reported frequency of cannabis use, reported cannabis use problems, recent use of other illicit drugs, tobacco dependence, alcohol use disorder, depression, generalized anxiety disorder, and psychotic-like experiences. The study used secondary data; consequently, the hypotheses were formulated after data collection.

Results: Past-year cannabis use was reported by 1087 participants (580 women; mean [SD] age at onset of cannabis use, 16.7 [3.0] years). Of these, 141 participants (13.0%) reported the use of high-potency cannabis. Use of high-potency cannabis was associated with increased frequency of cannabis use (adjusted odds ratio [AOR], 4.38; 95% CI, 2.89-6.63), cannabis problems (AOR, 4.08; 95% CI, 1.41-11.81), and increased likelihood of anxiety disorder (AOR, 1.92; 95% CI, 1.11-3.32). Adjustment for frequency of cannabis use attenuated the association with psychotic experiences (AOR 1.29; 95% CI, 0.67-2.50), tobacco dependence (AOR, 1.42; 95% CI, 0.89-2.27), and other illicit drug use (AOR, 1.29; 95% CI, 0.77-2.17). There was no evidence of association between the use of high-potency cannabis and alcohol use disorder or depression.

Conclusions And Relevance: To our knowledge, this study provides the first general population evidence suggesting that the use of high-potency cannabis is associated with mental health and addiction. Limiting the availability of high-potency cannabis may be associated with a reduction in the number of individuals who develop cannabis use disorders, the prevention of cannabis use from escalating to a regular behavior, and a reduction in the risk of mental health disorders.

Citing Articles

Mental automatism and exogenous psychosis: the originality of De Clérambault's and Karl Bonhoeffer's theories in substance-related psychoses.

Ricci V, Sarni A, Maina G Front Psychiatry. 2025; 16:1532730.

PMID: 39950170 PMC: 11821583. DOI: 10.3389/fpsyt.2025.1532730.

An analysis of the cultivation, consumption and composition of home-grown cannabis following decriminalisation in the Australian Capital Territory.

Zhou C, Lavender I, Gordon R, McCartney D, Kevin R, Bedoya-Perez M Sci Rep. 2025; 15(1):2649.

PMID: 39905040 PMC: 11794705. DOI: 10.1038/s41598-024-84897-w.

Cannabis Use Cessation and the Risk of Psychotic Disorders: A Case-Control Analysis from the First Episode Case-Control EU-GEI WP2 Study: L'arrêt de l'utilisation du cannabis et le risque de troubles psychotiques: Une analyse cas-témoins tirée de....

Bond B, Duric B, Spinazzola E, Trotta G, Chesney E, Li Z Can J Psychiatry. 2025; 70(3):182-193.

PMID: 39810593 PMC: 11733868. DOI: 10.1177/07067437241290187.

Does maternal education moderate the relationship between adolescent cannabis use and mental health in early adulthood?.

Sawyer G, Howe L, Hickman M, Zammit S, Hines L Drug Alcohol Rev. 2024; 43(7):1773-1780.

PMID: 39252481 PMC: 7616805. DOI: 10.1111/dar.13945.

Exploring the relationship between frequent cannabis use, belief updating under uncertainty and psychotic-like symptoms.

Liang X, Avram M, Gibbs-Dean T, Chesney E, Oliver D, Wang S Front Psychiatry. 2024; 15:1309868.

PMID: 39114739 PMC: 11304345. DOI: 10.3389/fpsyt.2024.1309868.

References

Hines L, Morley K, Rijsdijk F, Strang J, Agrawal A, Nelson E . Overlap of heritable influences between cannabis use disorder, frequency of use and opportunity to use cannabis: trivariate twin modelling and implications for genetic design. Psychol Med. 2018; 48(16):2786-2793. DOI: 10.1017/S0033291718000478. View

Sullivan S, Kounali D, Cannon M, David A, Fletcher P, Holmans P . A Population-Based Cohort Study Examining the Incidence and Impact of Psychotic Experiences From Childhood to Adulthood, and Prediction of Psychotic Disorder. Am J Psychiatry. 2020; 177(4):308-317. DOI: 10.1176/appi.ajp.2019.19060654. View

Freeman T, Morgan C, Hindocha C, Schafer G, Das R, Curran H . Just say 'know': how do cannabinoid concentrations influence users' estimates of cannabis potency and the amount they roll in joints?. Addiction. 2014; 109(10):1686-94. DOI: 10.1111/add.12634. View

Moore T, Zammit S, Lingford-Hughes A, Barnes T, Jones P, Burke M . Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet. 2007; 370(9584):319-28. DOI: 10.1016/S0140-6736(07)61162-3. View

Freeman T, Groshkova T, Cunningham A, Sedefov R, Griffiths P, Lynskey M . Increasing potency and price of cannabis in Europe, 2006-16. Addiction. 2019; 114(6):1015-1023. PMC: 6590252. DOI: 10.1111/add.14525. View

Di Forti M, Marconi A, Carra E, Fraietta S, Trotta A, Bonomo M . Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study. Lancet Psychiatry. 2015; 2(3):233-8. DOI: 10.1016/S2215-0366(14)00117-5. View

Hall W, Lynskey M . Why it is probably too soon to assess the public health effects of legalisation of recreational cannabis use in the USA. Lancet Psychiatry. 2016; 3(9):900-6. DOI: 10.1016/S2215-0366(16)30071-2. View

Boyd A, Golding J, Macleod J, Lawlor D, Fraser A, Henderson J . Cohort Profile: the 'children of the 90s'--the index offspring of the Avon Longitudinal Study of Parents and Children. Int J Epidemiol. 2012; 42(1):111-27. PMC: 3600618. DOI: 10.1093/ije/dys064. View

Lewis G, Pelosi A, Araya R, Dunn G . Measuring psychiatric disorder in the community: a standardized assessment for use by lay interviewers. Psychol Med. 1992; 22(2):465-86. DOI: 10.1017/s0033291700030415. View

10.

Gobbi G, Atkin T, Zytynski T, Wang S, Askari S, Boruff J . Association of Cannabis Use in Adolescence and Risk of Depression, Anxiety, and Suicidality in Young Adulthood: A Systematic Review and Meta-analysis. JAMA Psychiatry. 2019; 76(4):426-434. PMC: 6450286. DOI: 10.1001/jamapsychiatry.2018.4500. View

11.

Cascini F, Aiello C, Di Tanna G . Increasing delta-9-tetrahydrocannabinol (Δ-9-THC) content in herbal cannabis over time: systematic review and meta-analysis. Curr Drug Abuse Rev. 2011; 5(1):32-40. DOI: 10.2174/1874473711205010032. View

12.

DSouza D, Perry E, Macdougall L, Ammerman Y, Cooper T, Wu Y . The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology. 2004; 29(8):1558-72. DOI: 10.1038/sj.npp.1300496. View

13.

Di Forti M, Quattrone D, Freeman T, Tripoli G, Gayer-Anderson C, Quigley H . The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study. Lancet Psychiatry. 2019; 6(5):427-436. PMC: 7646282. DOI: 10.1016/S2215-0366(19)30048-3. View

14.

Potter D, Hammond K, Tuffnell S, Walker C, Di Forti M . Potency of Δ -tetrahydrocannabinol and other cannabinoids in cannabis in England in 2016: Implications for public health and pharmacology. Drug Test Anal. 2018; 10(4):628-635. DOI: 10.1002/dta.2368. View

15.

Freeman T, Winstock A . Examining the profile of high-potency cannabis and its association with severity of cannabis dependence. Psychol Med. 2015; 45(15):3181-9. PMC: 4611354. DOI: 10.1017/S0033291715001178. View

16.

White I, Royston P, Wood A . Multiple imputation using chained equations: Issues and guidance for practice. Stat Med. 2011; 30(4):377-99. DOI: 10.1002/sim.4067. View

17.

Zammit S, Horwood J, Thompson A, Thomas K, Menezes P, Gunnell D . Investigating if psychosis-like symptoms (PLIKS) are associated with family history of schizophrenia or paternal age in the ALSPAC birth cohort. Schizophr Res. 2008; 104(1-3):279-86. DOI: 10.1016/j.schres.2008.04.036. View

18.

Heatherton T, Kozlowski L, Frecker R, Fagerstrom K . The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. Br J Addict. 1991; 86(9):1119-27. DOI: 10.1111/j.1360-0443.1991.tb01879.x. View

19.

Fraser A, Macdonald-Wallis C, Tilling K, Boyd A, Golding J, Davey Smith G . Cohort Profile: the Avon Longitudinal Study of Parents and Children: ALSPAC mothers cohort. Int J Epidemiol. 2012; 42(1):97-110. PMC: 3600619. DOI: 10.1093/ije/dys066. View

20.

Gage S, Munafo M, Macleod J, Hickman M, Davey Smith G . Cannabis and psychosis. Lancet Psychiatry. 2015; 2(5):380. DOI: 10.1016/S2215-0366(15)00108-X. View